Core Viewpoint - The Guangxi Fangchenggang City has achieved significant progress in high-quality market regulation during the "14th Five-Year Plan" period, particularly in the pharmaceutical and medical device sectors, with a 100% rate in risk issue handling and rectification [1] Group 1: Medical Device Industry - During the "14th Five-Year Plan," the registration volume of medical devices in Fangchenggang rose from the last position in the region to the fourth position [3] - The number of Class II medical device manufacturing enterprises increased from 3 to 40, indicating rapid industry growth [3] - Three innovative drugs received clinical trial approval, marking a historic breakthrough for the city [3] - The first Class III medical device registration certificate was granted, achieving a "zero breakthrough" in this category for Fangchenggang [3] Group 2: Regulatory and Support Mechanisms - The market regulation department has established professional service teams to enhance quality in key areas such as review, approval, and testing, facilitating faster market entry for medical products [3] - An expert service group has been formed to provide guidance on brand development and standard upgrades, creating a closed-loop service system to assist companies in overcoming development challenges [3] Group 3: Safety Regulation and Compliance - The safety regulation of food, drugs, industrial products, and special equipment has been strengthened, with a food safety inspection pass rate consistently above 99.55% [4] - The completion rate for handling non-compliant samples has maintained 100% for five consecutive years [4] - A total of 733 cases of illegal activities in the pharmaceutical sector were addressed, fostering a fair and orderly market environment for the pharmaceutical industry [4] - The drug inspection capacity has significantly improved, with relevant qualification projects increasing by 13.22 times compared to the end of the "13th Five-Year Plan" [4]

Regulatory Developments - The National Health Commission and other departments have released the 2025 National Random Supervision and Inspection Plan, which includes new regulatory areas such as internet diagnosis and treatment, and mental health, while explicitly targeting online medical fraud [1] - The regulatory focus on combating online medical fraud represents a significant upgrade in medical supervision, aiming to purify the medical online space [1] Pharmaceutical Approvals - Innovent Biologics announced that its third-generation EGFR TKI drug, Olitinib (Leratinib), has received approval from the National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [2] - Olitinib is the only approved third-generation EGFR TKI based on a naphthalene structure, expanding treatment options for EGFR mutation-positive NSCLC patients [2] Market Regulation and Antitrust Issues - Xianju Pharmaceutical is facing a potential fine of approximately 195 million yuan for alleged monopolistic practices related to the pricing of dexamethasone phosphate raw materials, with the case still under review by the Tianjin Market Supervision Administration [3] - This incident highlights the regulatory authorities' emphasis on antitrust measures within the pharmaceutical industry, which could disrupt normal market operations [3] Combination Therapy Approvals - Pfizer announced that its oral targeted drug, Axi-cabtagene ciloleucel (Axitinib), has been approved for first-line treatment in combination with Toripalimab for high-risk, unresectable, or metastatic renal cell carcinoma (RCC) patients [4] - This approval marks the first and only approved first-line targeted and immune combination therapy for advanced kidney cancer in China, indicating a shift towards combination therapies in the treatment landscape [4]